Frankfurt
08.09.25 | 15:29
7,450 Euro
+4,20 % +0,300
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.08. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 27.08. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 1 | GlobeNewswire (USA) | ||
| NANOBIOTIX SA ADR Aktie jetzt für 0€ handeln | |||||
| 11.07. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 07.07. | Nanobiotix S.A.: NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3) | 689 | GlobeNewswire (Europe) | Health authorities in major European countries have accepted the reclassification of JNJ-1900 (NBTXR3) from a medical device to a medicinal product, aligning with regulatory status in the US and other... ► Artikel lesen | |
| 02.07. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.06. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 10 | GlobeNewswire (USA) | ||
| 10.06. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 21.05. | Nanobiotix S.A. reports Q1 results | 4 | Seeking Alpha | ||
| 21.05. | Nanobiotix S.A.: Nanobiotix Provides First Quarter 2025 Operational and Financial Update | 197 | GlobeNewswire (Europe) | Dosing of a first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial for patients with stage 3 unresectable non-small cell lung cancerPresentation of data at the European... ► Artikel lesen | |
| 21.05. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 14.05. | Nanobiotix S.A. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 14.05. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 1 | GlobeNewswire (USA) | ||
| 12.05. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 05.05. | Nanobiotix Reveals Favorable Results Of JNJ-1900 Study Pancreatic Cancer; Seeks Further Evaluation | 467 | AFX News | NEW BRUNSWICK (dpa-AFX) - Nanobiotix S.A. (NBTX), a biotechnology company focused on nanoparticle-based cancer treatments, announced Monday positive full results from the completed dose escalation... ► Artikel lesen | |
| 05.05. | Nanobiotix S.A.: Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer | 303 | GlobeNewswire (Europe) | Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall Survival... ► Artikel lesen | |
| 30.04. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 14.04. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 2 | GlobeNewswire (USA) | ||
| 10.04. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 04.04. | Guggenheim cuts Nanobiotix stock target to $8, maintains buy | 6 | Investing.com | ||
| 02.04. | Nanobiotix GAAP EPS of -€1.44 | 1 | Seeking Alpha |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | - | - | Boehringer Ingelheim Limited: Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases | · Collaboration strengthens Boehringer's pipeline in Eye Health.· Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,860 | -2,62 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 64,16 | -0,53 % | Halozyme auf Morgan Stanley Konferenz: Strategische Innovationen und starkes Wachstum im Fokus | ||
| AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
| ABCELLERA BIOLOGICS | 3,587 | +1,04 % | AbCellera: Strategischer Schwenk zur eigenen Pipeline bei solider Finanzlage | ||
| GLOW LIFETECH | 0,029 | -1,72 % | Glow Lifetech Corp.: Glow Lifetech Reports 196% YoY Revenue Growth and Improved Cash Flow in Q2 2025, Sets Stage for Continued Momentum in H2 | Toronto, Ontario--(Newsfile Corp. - August 28, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the second... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 243,80 | -1,30 % | Bio-Rad auf Wells Fargo Konferenz: Strategisches Wachstum trotz Herausforderungen | ||
| BIOLINERX | 2,885 | +3,40 % | XFRA YP2: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 1,530 | 0,00 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | MORRISTOWN, N.J., Aug. 7, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to... ► Artikel lesen | |
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals, Inc.: Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE in Chronic Rhinosinusitis (CRS) | Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10-million-patient marketAcquisition advances Paratek's vision... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 1,930 | +2,12 % | Minerva Neurosciences, Inc: Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results | FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia
Evaluation of strategic alternatives
BURLINGTON, Mass., Aug. 14, 2025(Nasdaq:... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,399 | +5,81 % | Applied Therapeutics Reports Second Quarter 2025 Financial Results | - CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD - Presented full 12-month clinical results and new topline data from INSPIRE... ► Artikel lesen | |
| OVID THERAPEUTICS | 1,000 | -5,66 % | Ovid Therapeutics Inc.: Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties | NEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions... ► Artikel lesen | |
| GEOVAX LABS | 2,685 | -100,00 % | GeoVax Labs: Strategische Impfstoff-Entwicklungen und Finanzierungspläne vorgestellt | ||
| COCRYSTAL | 1,250 | +0,81 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs | Favorable CDI-988 Phase 1 safety and tolerability reported Challenge study with CDI-988 as a norovirus preventive and treatment planned later this year BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen |
Das Unternehmen NANOBIOTIX SA ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,300 (+4,20 %) liegt der Kurs bei 7,450 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOBIOTIX SA ADR finden Sie auf Wallstreet Online.